Ann: Actinogen receives $4.8 million R&D tax incentive rebate, page-7

For starters you only get the rebate for eligible expenditure. So it is likely that a good CFO can ensure that the rebate is maximised to the extent permissible. Someone with this prior experience can be very worthwhile. I think he was involved in bringing an NZ therapeutic company to the ASX as an IPO in 2013 so has great experience in this tax rebate area before joining ACW. The tax rebate would be the responsibility of the CFO as he is the one who would ultimately be the person signing the tax return and attached R&D schedule of eligible expenditure.